Pfizer offers a 7% dividend yield, nearly triple the S&P 500 average. While the payout ratio has improved, earnings could face pressure through 2028 due to patent cliffs and pipeline uncertainties, making it a risky income play despite the attractive yield.

The pharmaceutical giant’s dividend of $0.43 per share translates to an annual yield of 7%. With dividends paid for 345 consecutive quarters and raised annually for 16 years, recent increases have been minimal. Management projects adjusted earnings for 2025, which could bring the payout ratio down to a more comfortable range.

Pfizer faces patent expirations on major drugs, potentially impacting 30% of current annual revenue. While a $7.2 billion cost-cutting program helps, revenue losses from patent cliffs remain a concern despite the Seagen acquisition for pipeline renewal.

Risk factors for Pfizer include uncertainty in the organic pipeline, missed opportunities like the discontinued obesity drug program, and stable but non-growth COVID-related products. Analysts view upcoming vaccine programs as incremental rather than transformative, posing challenges amid patent expiries.

Pfizer’s 7% yield may seem attractive, but the company trades at just 8.1 times forward earnings, reflecting market skepticism. While the dividend appears safe through 2026, long-term uncertainties lie ahead, with a comparison to peers showing lower yields but greater dividend security.

Investing in Pfizer solely for its dividend involves navigating various risks, including patent cliffs, pipeline setbacks, and cost restructuring. The 7% yield may survive the next few years with token increases, but long-term growth prospects are uncertain, making it a risky investment choice.

Read more at Yahoo Finance: Income Gem or Value Trap?